Sorrento Therapeutics is a clinical stage and commercial biopharma company focused on delivering therapies to patients and their families. Co. has two segments: The Sorrento Therapeutics segment, which is organized around its Immune-Oncology therapeutic area, using its proprietary G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, antibody drug conjugates as well as bispecific antibody approaches. The Scilex segment is mainly organized around Co.'s non-opioid pain management operations. The SRNE stock yearly return is shown above.
The yearly return on the SRNE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SRNE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|